对RSV的Clesrovimab批准:为全球婴儿健康公平提供一个拯救生命的机会
Sakshi Kumari1, Kamil Ahmad Kamil2
1Internal Medicine Department, Shimoga Institute of Medical Sciences, Shimoga, India.
Annals of medicine and surgery (2012)
|March 6, 2026
概括
克莱斯罗维马布是一种新的单克隆抗体,可显著减少婴儿在第一个呼吸道同胞病毒 (RSV) 季节的住院和感染. 这一进步为全球脆弱的婴儿提供了对RSV的关键保护.
科学领域:
- 儿科 儿科 儿科
- 免疫学 免疫学 免疫学
- 传染性疾病 传染性疾病
背景情况:
- 呼吸道同胞病毒 (RSV) 是导致婴儿死亡的主要原因,特别是在资源较低的环境中.
- 在全球范围内,对支持性护理的有限访问加剧了RSV相关的死亡,在脆弱的婴儿群体中.
研究的目的:
- 评估新型单克隆抗体clesrovimab的疗效和安全性,以保护婴儿免受RSV的感染.
- 评估克莱斯罗维马布对减少RSV相关住院和婴儿下呼吸道感染的影响.
主要方法:
- 进行了2b/3期临床试验,以评估克莱斯罗维马布的有效性.
- 在高风险儿科组中,安全性资料与现有的预防性治疗方法进行了比较.
主要成果:
- 克莱斯罗维马布显示,RSV相关住院病例减少了84.3%.
- 观察到医疗护理下呼吸道感染病例减少了60.5%.
- 单克隆抗体的安全性与目前高风险婴儿的治疗方法相比较.
结论:
- 克莱斯罗维马布在婴儿RSV预防方面取得了重大进展,特别是在高收入国家.
- 公平的获取和负担能力对于减少RSV的全球负担至关重要,特别是在资源有限的地区.
- 这种干预措施有可能降低全球脆弱婴儿的RSV相关发病率和死亡率.
关键词:
在CLEVER审判中,美国食品和药物管理局 (FDA) 批准这是一个LMIC.这就是为什么RSV RSV.在SMART试验中,克莱斯罗维马布的情况全球儿童健康儿童健康卫生公平性健康公平性婴儿死亡率 婴儿死亡率这是一种单克隆抗体.这里有vizumab.更多相关视频
相关概念视频
Rous Sarcoma Virus (RSV) and Cancer
6.5K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
6.5K
FDA Approved Drugs: Changes to Approved Drugs
301
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
301
Acute Respiratory Failure-IV
638
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
638
Subviral Agents
693
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
693
Acute Respiratory Failure-V
564
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
564
Acute Respiratory Failure-II
1.3K
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
1.3K


